Income Statement for RNAZ

	Transcode Therapeutics, Inc. (RNAZ)
	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014
Balance Sheet Date			2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31	2023-Sep-30	2023-Jun-30	2023-Mar-31	2022-Dec-31	2022-Sep-30	2022-Jun-30	2022-Mar-31	2021-Dec-31	2021-Sep-30	2021-Jun-30
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023	Q3-FY2023	Q2-FY2023	Q1-FY2023	Q4-FY2022	Q3-FY2022	Q2-FY2022	Q1-FY2022	Q4-FY2021	Q3-FY2021	Q2-FY2021
Total Revenue
QoQ%
YoY%
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses			16,026,557$	4,561,200$	4,221,134$	3,171,179$	5,092,388$	2,165,412$	5,113,916$	3,288,982$	4,097,588$	5,310,252$	5,122,993$	4,887,684$	5,495,473$	4,953,560$	4,707,293$	3,477,502$	2,986,234$	2,359,909$	355,528$	449,465$	379,001$	239,491$	91,605$
Operating Income			(16,026,557$)	(4,561,200$)	(4,221,134$)	(3,171,179$)	(5,092,388$)	(2,165,412$)	(5,113,916$)	(3,288,982$)	(4,097,588$)	(5,310,252$)	(5,122,993$)	(4,887,684$)	(5,495,473$)	(4,953,560$)	(4,707,293$)	(3,477,502$)	(2,986,234$)	(2,359,909$)	(355,528$)	(449,465$)	(379,001$)	(239,491$)	(91,605$)
Operating Margin
Interest Income			78,757$	147$	148$	146$	159$	179$	178$	168$	137$	131$	246$	4,770$	9,636$	9,001$	1,331$	442$	510$	141$	1$	12$	22$	28$	57$
Interest Expenses						114$	1,832$	10,792$	4,482$	9,706$	17,345$	17,282$	7,843$	13,429$					0$	333$	41,966$	52,770$	53,864$	280,277$	35,650$
Income Before Tax			(13,217,041$)	(4,856,051$)	(4,276,502$)	(12,085,413$)	(5,915,958$)	(2,321,387$)	(5,190,814$)	(3,326,812$)	(4,087,547$)	(5,299,962$)	(4,341,652$)	(4,816,934$)	(5,134,056$)	(4,289,610$)	(4,671,232$)	(3,470,070$)	(2,746,208$)	(2,329,706$)	2,770,904$	(4,485,338$)	(801,531$)	(1,373,904$)	(127,198$)
Tax Expenses			226,069$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	53,051$	0$	0$	0$	0$	0$	0$
Net Income			(13,443,110$)	(4,856,051$)	(4,276,502$)	(12,085,413$)	(5,915,958$)	(2,321,387$)	(5,190,814$)	(3,326,812$)	(4,087,547$)	(5,299,962$)	(4,341,652$)	(4,816,934$)	(5,134,056$)	(4,289,610$)	(4,671,232$)	(3,470,070$)	(2,799,259$)	(2,329,706$)	2,770,904$	(4,485,338$)	(801,531$)	(1,373,904$)	(127,198$)
Profit Margin
TTM
Earnings to Minority			1,610,211$				30,601$						1$
Earnings to Common Shareholders			(15,053,321$)	(4,856,051$)	(4,276,502$)	(12,085,413$)	(5,946,559$)	(2,321,387$)	(5,190,814$)	(3,326,812$)	(4,087,547$)	(5,299,962$)	(4,341,653$)	(4,816,934$)	(5,134,056$)	(4,289,610$)	(4,671,232$)	(3,470,070$)	(2,799,259$)	(2,329,706$)	2,770,904$	(4,485,338$)	(801,531$)	(1,373,904$)	(127,198$)
QoQ%			(209.99%)	(13.55%)	64.61%	(103.23%)	(156.16%)	55.28%	(56.03%)	18.61%	22.88%	(22.07%)	9.87%	6.18%	(19.69%)	8.17%	(34.62%)	(23.96%)	(20.16%)	(184.08%)	161.78%	(459.60%)	41.66%	(980.13%)
YoY%			(153.14%)	(109.19%)	17.61%	(263.27%)	(45.48%)	56.20%	(19.56%)	30.94%	20.38%	(23.55%)	7.06%	(38.81%)	(83.41%)	(84.13%)	(268.58%)	22.64%	(249.24%)	(69.57%)	2,278.42%
Earnings Per Share, Basic			4.03$	(5.82$)	(5.13$)	(2.51$)	46.05$	(146.06$)	(680.23$)	(21.35$)	29.88$	(48.44$)	(142.38$)	(259.07$)	0.36$	(6.61$)	(7.20$)	(0.27$)	(0.22$)	(0.20$)	0.60$	(0.97$)		(0.30$)	(0.03$)
Earnings Per Share, Diluted			4.03$	(5.82$)	(5.13$)	(2.51$)	46.05$	(146.06$)	(680.23$)	(21.35$)	29.88$	(48.44$)	(142.38$)	(259.07$)	0.36$	(6.61$)	(7.20$)	(0.27$)	(0.23$)	(0.20$)	0.51$	(0.97$)		(0.30$)	(0.03$)
Unlevered FCF Per Share, Basic			2.18$	(4.90$)	(5.03$)	(0.64$)	24.37$	(246.99$)	(307.21$)	(25.29$)	41.40$	(32.08$)	(144.61$)	(243.45$)	0.28$	(6.82$)	(5.26$)	(0.31$)	(0.13$)	(0.27$)		(0.13$)		(0.03$)
Unlevered FCF Per Share, Diluted			2.18$	(4.90$)	(5.03$)	(0.64$)	24.37$	(246.99$)	(307.21$)	(25.29$)	41.40$	(32.08$)	(144.61$)	(243.45$)	0.28$	(6.82$)	(5.26$)	(0.31$)	(0.14$)	(0.27$)		(0.13$)		(0.03$)
Average Shares, Basic			-3,731,802	833,683	833,654	4,823,317	-129,123	15,893	7,631	155,831	-136,804	109,413	30,494	18,593	-14,210,070	648,862	648,862	12,977,234	12,904,574	11,526,514	4,636,216	4,636,216		4,636,216	4,636,216
Average Shares, Diluted			-3,731,802	833,683	833,654	4,823,317	-129,123	15,893	7,631	155,831	-136,804	109,413	30,494	18,593	-14,210,070	648,862	648,862	12,977,234	12,140,606	11,526,514	5,400,184	4,636,216		4,636,216	4,636,216
EBIT			(13,217,041$)	(4,856,051$)	(4,276,502$)	(12,085,299$)	(5,914,126$)	(2,310,595$)	(5,186,332$)	(3,317,106$)	(4,070,202$)	(5,282,680$)	(4,333,809$)	(4,803,505$)	(5,134,056$)	(4,289,610$)	(4,671,232$)	(3,470,070$)	(2,746,208$)	(2,329,373$)	2,812,870$	(4,432,568$)	(747,667$)	(1,093,627$)	(91,548$)
EBITDA			(13,172,261$)	(4,851,270$)	(4,263,059$)	(12,071,856$)	(5,903,780$)	(2,294,564$)	(5,153,978$)	(3,284,942$)	(4,038,547$)	(5,251,462$)	(4,302,839$)	(4,773,865$)	(5,104,551$)	(4,264,808$)	(4,648,534$)	(3,448,469$)	(2,717,220$)	(2,329,373$)	2,812,870$	(4,431,314$)	(747,667$)	(1,093,627$)	(91,548$)